- Scipher Medicine announced that Galapagos (NASDAQ:GLPG) has exercised its option to in-license novel drug targets for inflammatory bowel disease (IBD) discovered by Scipher's Spectra platform.
- In August 2020, Galapagos and Scipher Medicine agreed to jointly validate a suite of novel IBD targets discovered by Spectra. Galapagos has the exclusive option to in-license certain validated preclinical targets for further development and commercialization.
- After validation work, Galapagos is moving selected targets into the next phase of drug development, triggering a milestone payment to Scipher and making Scipher eligible to receive additional milestone-based payments.
- Spectra is fueled by one of the largest patient molecular data lakes in autoimmune diseases and unique artificial intelligence network science-based algorithms. The platform identifies biologically similar patients and drug targets specific to those patients to improve response rates.
- Price Action: GLPG shares are up 0.58% at $55.58 during the market session on the last check Tuesday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
Galapagos In-licenses Inflammatory Bowel Disease Drug Targets From Scipher Medicine
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks